Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of oral sildenafil three times daily in adults with pulmonary arterial hypertension
2006-006748-76Phase 4Terminated
- Sponsor
- Pfizer
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sildenafil in pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) (3 arms), sponsored by Pfizer. Primary endpoint: Change from baseline in 6-minute walk test distance at Week 12. Started Nov 2007; status: terminated.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2006-006748-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006748-76.